$ARNA (Arena Pharmaceuticals Inc)

$ARNA {{ '2015-11-10T22:27:10+0000' | timeago}} • Webcast

$ARNA's research and development expenses for 3Q15 decreased to $22.1MM from $24.5MM for 3Q14. R&D expenses for the last quarter included $2.1MM in non-cash shared based compensation expense compared to $1.8MM for the same quarter of last year.

$ARNA {{ '2017-03-14T20:45:36+0000' | timeago}} • Announcement

$ARNA's renegotiation of an agreement with Eisai is expected to provide Arena with $23MM of cash payments, including $10MM received in 4Q16, and over $80MM of potential cost relief on lorcaserin (a weight loss drug) development obligations in the next three years.

$ARNA {{ '2017-03-14T20:39:09+0000' | timeago}} • Announcement

$ARNA sees FY17 net cash used in operating and investing activities to be $80-100MM, assuming no additional partnerships and no adjustment to its development plans. Also, $ARNA hopes to report results from all three of its proprietary Phase 2 programs this year.

$ARNA {{ '2017-03-14T20:27:43+0000' | timeago}} • Announcement

$ARNA's revenue shot up 10 times to $85.3MM in 4Q16, helped by $66.1MM of revenue associated with upfront BELVIQ payments. This helped $ARNA swing to a net income of $38.3MM, or $0.16 per share, from a loss of $30.4MM, or $0.13 per share in the same quarter last year.

$ARNA {{ '2015-12-15T19:01:11+0000' | timeago}} • SEC

$ARNA's interest and other income (expense), net, was expense of $1.2MM in 3Q15, compared to income of $15.5MM in 3Q14. This change of $16.7MM was mainly due to a gain on sale of available-for-sale securities of $16.3MM realized in 3Q14 related to its sale of shares $ARNA held in TaiGen Biotechnology Co., Ltd.

$ARNA {{ '2015-12-15T18:56:01+0000' | timeago}} • SEC

$ARNA's research and development expenses fell by $2.4MM to $22.1MM in 3Q15, from $24.5MM in 3Q14. This decrease was mainly due to a decrease of $2.4MM in external clinical and preclinical study fees and internal non-commercial manufacturing costs.

$ARNA {{ '2015-11-10T22:28:51+0000' | timeago}} • Webcast

$ARNA's general and administrative expenses increased slightly to $9MM for 3Q15 compared to $8MM for same quarter of last year. G&A expenses for the last quarter included $1.8MM in non-cash share-based compensation expense, compared to $1.6MM for the third quarter of 2014.

$ARNA {{ '2015-11-10T22:27:10+0000' | timeago}} • Webcast

$ARNA's research and development expenses for 3Q15 decreased to $22.1MM from $24.5MM for 3Q14. R&D expenses for the last quarter included $2.1MM in non-cash shared based compensation expense compared to $1.8MM for the same quarter of last year.

$ARNA {{ '2015-11-10T22:24:18+0000' | timeago}} • Webcast

On the $ARNA's BELVIQ front, Ildong Pharmaceutical Co., Ltd., estimates that approx. 2.1MM tablets of BELVIQ were prescribed in South Korea in 3Q15, which equates to approx. 34,400 one-month prescriptions, representing growth in total prescriptions of approx. 18.6% compared to the previous quarter.

$ARNA {{ '2015-11-10T22:23:52+0000' | timeago}} • Webcast

On the $ARNA's BELVIQ front, IMS Health estimates that approx. 157,000 prescriptions for BELVIQ were filled in the US in 3Q15, representing growth in total prescriptions of approx. 9.8% compared to the same quarter of last year and a decrease of 14.4% compared to the previous quarter.

$ARNA {{ '2015-11-10T22:23:13+0000' | timeago}} • Webcast

During 3Q15, $ARNA's Eisai shipped approx. 106,000 60-count bottles of BELVIQ and Ildong shipped approx. 43,000 60-count bottles of BELVIQ to wholesalers. For the U.S., the gross to net discount was 53%, which reflects pay no more than $75 savings card program implemented by Eisai in January 2015.

$ARNA {{ '2015-11-10T21:52:23+0000' | timeago}} • Announcement

At 3Q15-end, $ARNA's cash and cash equivalents totaled $181.3MM and approx. 242.4MM shares of common stock were outstanding.

$ARNA {{ '2015-11-10T21:50:28+0000' | timeago}} • Announcement

During 3Q15, $ARNA announced the initiation of a Phase 1b multiple-ascending dose clinical trial of APD371, a selective and potent agonist of the cannabinoid 2 receptor.

$ARNA {{ '2015-11-10T21:49:55+0000' | timeago}} • Announcement

During 3Q15, $ARNA announced the initiation of a Phase 2 proof-of-concept clinical trial of APD334, an oral Sphingosine 1-Phosphate Subtype 1 receptor modulator for autoimmune diseases, being studied in this trial for the treatment of ulcerative colitis.

$ARNA {{ '2015-11-10T21:49:22+0000' | timeago}} • Announcement

During 3Q15, $ARNA announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its R&D priorities. As part of this initiative, $ARNA reduced its US workforce by about 80 employees or 35%, which is expected to reduce annualized cash expenditures for personnel by $11MM.

$ARNA {{ '2015-11-10T21:48:22+0000' | timeago}} • Announcement

$ARNA posted a net loss of $26.4MM or $0.11 per diluted share, which compares unfavorably to a net loss of $10.67MM or $0.05 per diluted share from a year ago period. The company's revenues came in at $9.1MM, which represents an increase of 11.52% YoverY and includes $4.9MM in net product sales of BELVIQ.

$ARNA {{ '2015-09-09T14:37:28+0000' | timeago}} • SEC

As of business close on Aug. 4, 2015, there were 242,241,710 shares of $ARNA's common stock outstanding. Also, as of Aug. 4, 2015, $ARNA had outstanding a warrant to purchase 1,965,418 shares of its common stock at an exercise price of $4.34 per share that expires on Aug. 14, 2015.

$ARNA {{ '2015-09-09T14:32:25+0000' | timeago}} • SEC

G&A expenses in 2Q15 were $8.8MM, down $0.3MM or 3.3% from $9.1MM in 2Q14. The decline was mainly due to a $0.5MM decrease in patent and trademark fees. $ARNA expects G&A expenses in 2015 to be higher than that of 2014. R&D expenses in 2Q15 were $24.2MM, down $2.8MM from $27MM in the same period last year.

$ARNA {{ '2015-09-09T14:10:49+0000' | timeago}} • Announcement

$ARNA is qualified to receive payments upon regulatory approval of BELVIQ under the Teva agreement for weight loss or weight management. If BELVIQ is approved in the applicable territory, $ARNA will sell BELVIQ to Teva for a purchase price of 35% of Teva's annual net product sales.

$ARNA {{ '2015-09-09T14:10:40+0000' | timeago}} • SEC

$ARNA's revenues from its portion of Eisai net product sales of BELVIQ were $3.9MM during the quarter ended June 30, 2015. Of the $3.9MM, $3.8MM related to the sales at the Eisai product purchase price and $0.1MM related to voucher redemptions.

$ARNA {{ '2015-09-09T14:10:27+0000' | timeago}} • SEC

As of June 30, 2015, $ARNA's cash ratio was 3.5 compared to 3.28 as of June 30, 2014. Cash and cash equivalents at the end of 2Q15 were $216.7MMM compared to $200.8MM at the end of 2Q14.

Recent Transcripts

NVO (Novo Nordisk A/S)
Thursday, August 10 2017 - 12:15pm
ARRY (Array BioPharma Inc.)
Wednesday, August 9 2017 - 1:00pm
CEMP (Cempra, Inc.)
Wednesday, August 9 2017 - 12:45pm
PGNX (Progenics Pharmaceuticals, Inc.)
Wednesday, August 9 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
NVO (Novo Nordisk A/S)
Wednesday, August 9 2017 - 11:00am
TBPH (Theravance Biopharma, Inc.)
Tuesday, August 8 2017 - 9:00pm
OREX (Orexigen Therapeutics, Inc.)
Tuesday, August 8 2017 - 9:00pm
ARNA (Arena Pharmaceuticals Inc)
Monday, August 7 2017 - 8:30pm
SPPI (Spectrum Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 8:30pm
CERS (Cerus Corporation)
Thursday, August 3 2017 - 8:15pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
RIGL (Rigel Pharmaceuticals, Inc.)
Tuesday, August 1 2017 - 9:00pm
RARE (Ultragenyx Pharmaceutical Inc.)
Thursday, July 27 2017 - 9:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, July 27 2017 - 8:30pm
GSK (GlaxoSmithKline plc)
Wednesday, July 26 2017 - 1:00pm
TRIB (Trinity Biotech plc)
Thursday, July 20 2017 - 3:00pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
OREX (Orexigen Therapeutics, Inc.)
Tuesday, May 9 2017 - 9:00pm
ARNA (Arena Pharmaceuticals Inc)
Tuesday, May 9 2017 - 8:30pm

AlphaGraphics you may like